N
Nikolai Constantin Brun
Researcher at Genmab
Publications - 5
Citations - 1019
Nikolai Constantin Brun is an academic researcher from Genmab. The author has contributed to research in topics: Daratumumab & Lenalidomide. The author has an hindex of 5, co-authored 5 publications receiving 896 citations.
Papers
More filters
Journal ArticleDOI
Targeting CD38 with daratumumab monotherapy in multiple myeloma
Henk M. Lokhorst,Torben Plesner,Jacob P. Laubach,Hareth Nahi,Peter Gimsing,Markus Hansson,Monique C. Minnema,Ulrik Lassen,Ulrik Lassen,Jakub Krejcik,Antonio Palumbo,Niels W.C.J. van de Donk,Tahamtan Ahmadi,Imran Khan,Clarissa M. Uhlar,Jianping Wang,A. Kate Sasser,Nedjad Losic,Steen Lisby,Linda Basse,Nikolai Constantin Brun,Paul G. Richardson +21 more
TL;DR: Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma, and no maximum tolerated dose was identified in part 1.
Journal ArticleDOI
Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
Torben Plesner,Hendrik-Tobias Arkenau,Henk M. Lokhorst,Peter Gimsing,Jakub Krejcik,Charlotte Lemech,Monique C. Minnema,Ulrik Lassen,Jacob P. Laubach,Tahamtan Ahmadi,Howard Yeh,Mary E. Guckert,Huaibao Feng,Nikolai Constantin Brun,Steen Lisby,Linda Basse,Antonio Palumbo,Paul G. Richardson +17 more
TL;DR: DARA+LEN+DEX has favorable safety profile with manageable toxicities in relapsed and RR MM, and the most frequent (>30% patients) adverse events (AEs) were neutropenia and diarrhea; no dose limiting toxicities (DLTs) were reported.
Journal ArticleDOI
Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.
Torben Plesner,Hendrik-Tobias Arkenau,Henk M. Lokhorst,Peter Gimsing,Jakub Krejcik,Charlotte Lemech,Monique C. Minnema,Ulrik Lassen,Tahamtan Ahmadi,Howard Yeh,Mary E. Guckert,Nikolai Constantin Brun,Steen Lisby,Linda Basse,Antonio Palumbo,Paul G. Richardson +15 more
TL;DR: This first-in-human dose-escalation study evaluated safety, pharmacokinetics (PK) and efficacy of DARA + LEN + dexamethasone (DEX) in patients with relapsed or RR MM.
Journal ArticleDOI
Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).
Henk M. Lokhorst,Jacob P. Laubach,Hareth Nahi,Torben Plesner,P Gimsing,Markus Hansson,Monique C. Minnema,Ulrik Lassen,Jakub Krejcik,Tahamtan Ahmadi,Steen Lisby,Linda Basse,Nikolai Constantin Brun,Paul G. Richardson +13 more
TL;DR: Pts with RR MM received DARA for 9 wks in doses of 0.005-24mg/kg in the GEN501 dose-escalation part (Lokhorst: EHA 2013 abstract S576).
Journal ArticleDOI
Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma
Tobias Arkenau,Henk M. Lokhorst,Peter Gimsing,DMSci,Jakub Krejcik,Charlotte Lemech,Monique C. Minnema,Ulrik Lassen,Andrew Cakana,Nikolai Constantin Brun,Linda Basse,Antonio Palumbo,Paul G. Richardson +12 more
TL;DR: The first experience from the GEN503 study combining DARA with LEN and dexamethasone (DEX) shows that DARA induced a marked reduction in M-protein, yielding a response rate of PR or better, in line with what has previously been reported for LEN.